Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve diabetes outcomes but are not cost effective
1. For sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists to be used as first-line agents for type ...
